解析177Lu放射性配体治疗的表型反应以识别有效联合方案
该研究通过免疫荧光分析DNA损伤应答标志物,并在多种DDR缺陷同源细胞系和DDR抑制剂中筛选[177Lu]Lu-DOTA的增敏剂,发现NHEJ通路缺失对[177Lu]Lu-DOTA增敏最强。DNA-PK抑制可强烈增敏PSMA阳性前列腺癌细胞对[177Lu]Lu-PSMA-617的反应,加剧凋亡和细胞周期阻滞,并在体内改善疗效且耐受良好。
要点
- 177Lu-RLT诱导DNA双链断裂修复和基因组不稳定性相关DDR标志物。
- NHEJ通路缺失对[177Lu]Lu-DOTA的增敏作用最强。
- DNA-PK抑制强烈增敏PSMA阳性前列腺癌细胞对[177Lu]Lu-PSMA-617的反应。
核心结论
- NHEJ是修复177Lu诱导DNA损伤的关键通路,DNA-PK抑制可强烈增敏177Lu-RLT,值得临床探索联合方案。
研究设计与样本
- 在癌细胞系中以免疫荧光分析DDR标志物,并在DDR缺陷同源细胞系和DDR抑制剂中通过活力实验筛选[177Lu]Lu-DOTA增敏剂,进一步在体外和体内表征DNA-PK抑制联合177Lu-RLT的效果。
主要发现
- [177Lu]Lu-DOTA处理诱导多种提示DNA双链断裂修复和基因组不稳定性的DDR生物标志物。
- DDR缺陷同源模型和DDR抑制剂的活力实验显示,NHEJ通路缺失对[177Lu]Lu-DOTA的增敏作用最强。
- DNA-PK抑制强烈增敏PSMA阳性前列腺癌细胞对[177Lu]Lu-PSMA-617的反应,加剧凋亡和细胞周期阻滞,并在体内改善疗效且耐受良好。
临床怎么用
- DNA-PK抑制剂联合177Lu-RLT可作为增敏策略,尤其针对PSMA阳性前列腺癌,但需临床探索验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Radioligand therapy (RLT) delivers radionuclides, such as Lutetium-177 (177Lu), to selectively target cancer cells. Despite the favourable clinical outcomes of 177Lu-based RLT, complete cure remains infrequent. A comprehensive understanding of its mode of action (MoA) is essential for strategic design of novel combination approaches that could improve therapeutic responses. METHODS: DNA damage response (DDR) markers were profiled by immunofluorescence in cancer cell lines treated with DOTA-chelated 177Lu ([177Lu]Lu-DOTA). Multiple DDR-deficient isogenic cell lines and DDR inhibitors were screened in viability assays with [177Lu]Lu-DOTA to identify sensitizers. 177Lu-RLT combination with an inhibitor of the non-homologous end joining (NHEJ) core factor DNA-PK, and its effect on viability and cell death, were further characterised in vitro and in vivo. RESULTS: [177Lu]Lu-DOTA treatment induced multiple DDR biomarkers indicative of DNA double-strand break (DSB) repair and genomic instability. Viability assays performed with DDR-deficient isogenic models and DDR inhibitors demonstrated that loss of DSB repair through NHEJ elicits the strongest sensitisation to [177Lu]Lu-DOTA. Consistently, DNA-PK inhibition strongly sensitised PSMA-positive prostate cancer cells to [177Lu]Lu-PSMA-617, exacerbated apoptosis and cell cycle arrest and improved efficacy in vivo, demonstrating good tolerability. CONCLUSION: These results provide novel mechanistic insights into 177Lu-based RLT and pinpoint NHEJ as a key pathway for the repair of 177Lu-induced DNA damage. DNA-PK inhibition strongly sensitises cancer cells to 177Lu-based RLT and results in stronger potentiation compared with other tested DDR inhibitor combinations, warranting the clinical exploration of 177Lu-based RLT and DNA-PK inhibitor (DNA-PKi) combination.
引用
- Ranzani M, Cicconi A, Sastre-Moreno G, et al. Deciphering the phenotypic responses to 177Lu-based radioligand therapy to identify efficacious combinations. Eur J Nucl Med Mol Imaging. 2026. PMID: 42487019. doi:10.1007/s00259-026-08092-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。